Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

Diagnostic Microbiology and Infectious Disease

Volumn 48, Issue 2, 2004, Pages 137-143

  Streit, Jennifer M ^a   Fritsche, Thomas R ^a   Sader, Helio S ^a   Jones, Ronald N ^a,b  

^a JONES Group JMI Laboxratories   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CHLORAMPHENICOL; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; QUINUPRISTIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; WESTERN HEMISPHERE;

EID: 1242270459     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2003.09.004     Document Type: Article

References (17)

1. Anderegg T.R., Biedenbach D.J., Jones R.N. Initial quality control evaluations for susceptibility testing of dalbavancin (BI 397), an investigational glycopeptide with Gram-positive activity. J Clin Microbiol. 4:2003;2795-2796.
2. Baquero F. Gram-positive resistance challenge for the development of newantibiotics . J Antimicrob Chemother. 39:(Suppl A):1997;1-6.
3. Candiani G., Abbondi M., Borgonovi M., Romano G., Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semisynthetic glycopeptide antibiotic. J Antimicrob Chemother. 44:1999;179-192.
4. Staphylococcus aureus resistant to vancomycin United States, 2002 . Mor Mort Wkly Rep. 51:2002;565-567.
5. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., Shah S., Rudrik J.T., Pupp G.R., Brown W.J., Cardo D., Fridkin S.K. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 348:2003;1342-1347.
6. Goldstein B.P., Candiani G.P., Arain T.M., Romano G., Ciciliato I., Berti M., Abbondi M., Scotti R., Mainini M., Ripamonti F., Resconi A., Denaro M. Antimicrobial activity of MDL 63246, a new semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother. 39:1995;1580-1585.
7. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y., Tyrrell K., Fernandez H.T. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and Corynebacteria. Antimicrob Agents Chemother. 47:2003;1968-1971.
8. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar W., DenBesten K., Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. (letter) Lancet. 357:2001;1179.
9. Jones R.N., Streit J.M., Fritsche T.R. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents. 2003;. (in press).
10. Jones R.N., Biedenbach D.J., Johnson D.M., Pfaller M.A. In vitro evaluation of BI 397, a novel glycopepetide antimicrobial agent. J Chemother. 13:2001;244-254.
11. Mutnick A.H., Enne V., Jones R.N. Linezolid resistance since 2001 SENTRY Antimicrobial Surveillance Program . Ann Pharmacother. 37:2003;769-774.
12. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved standard M7-A6. 2003;NCCLS, Wayne, PA.
13. MIC testing. Performance standards for antimicrobial susceptibility testing (M100-S13). 2003;NCCLS, Wayne, PA.
14. Rhomberg P.R., Jones R.N., Mutnick A.H. Geographic variations and trends in key bacteremic pathogen resistance report from the SENTRY Antimicrobial Surveillance Program (1997-2001) . Programs and Abstracts of the 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy, poster C2-298. 2002.
15. Seltzer E., Goldstein B., Dorr M.mothershrey-B., Dowell J., Perry M., Henkel T. Dalbavancin Phase II demonstration of efficacy of a novel, weekly dosing regimen in skin and soft tissue infection, Abstr. 0143 . Clin Microbiol Infect. 9:(Suppl 1):2003;22.
16. Tsiodras A., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 358:2001;207-208.
17. Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Expert Opin Investig Drugs. 12:2003;117-137.